questionsmedicales.fr
Phénomènes génétiques
Phénotype
Sérogroupe
Sérogroupe : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Sérogroupe : Questions médicales les plus fréquentes",
"headline": "Sérogroupe : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Sérogroupe : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-30",
"dateModified": "2025-04-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Sérogroupe"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phénotype",
"url": "https://questionsmedicales.fr/mesh/D010641",
"about": {
"@type": "MedicalCondition",
"name": "Phénotype",
"code": {
"@type": "MedicalCode",
"code": "D010641",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.695"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Sérogroupe",
"alternateName": "Serogroup",
"code": {
"@type": "MedicalCode",
"code": "D065288",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ray Borrow",
"url": "https://questionsmedicales.fr/author/Ray%20Borrow",
"affiliation": {
"@type": "Organization",
"name": "Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom."
}
},
{
"@type": "Person",
"name": "Bo Pang",
"url": "https://questionsmedicales.fr/author/Bo%20Pang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. pangbo@icdc.cn."
}
},
{
"@type": "Person",
"name": "Biao Kan",
"url": "https://questionsmedicales.fr/author/Biao%20Kan",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. kanbiao@icdc.cn."
}
},
{
"@type": "Person",
"name": "Lucy A McNamara",
"url": "https://questionsmedicales.fr/author/Lucy%20A%20McNamara",
"affiliation": {
"@type": "Organization",
"name": "Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, Atlanta, USA."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma.",
"datePublished": "2023-09-08",
"url": "https://questionsmedicales.fr/article/37746265",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fonc.2023.1238883"
}
},
{
"@type": "ScholarlyArticle",
"name": "The miR-429 suppresses proliferation and migration in glioblastoma cells and induces cell-cycle arrest and apoptosis via modulating several target genes of ERBB signaling pathway.",
"datePublished": "2022-10-11",
"url": "https://questionsmedicales.fr/article/36219319",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11033-022-07903-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Protocol for identifying properties of ERBB receptor antagonists using the barcoded ERBBprofiler assay.",
"datePublished": "2024-04-16",
"url": "https://questionsmedicales.fr/article/38635397",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.xpro.2024.102987"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review.",
"datePublished": "2024-06-27",
"url": "https://questionsmedicales.fr/article/38988928",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.21037/tcr-24-837"
}
},
{
"@type": "ScholarlyArticle",
"name": "A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.",
"datePublished": "2023-06-14",
"url": "https://questionsmedicales.fr/article/37314501",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00280-023-04545-4"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phénotype",
"item": "https://questionsmedicales.fr/mesh/D010641"
},
{
"@type": "ListItem",
"position": 4,
"name": "Sérogroupe",
"item": "https://questionsmedicales.fr/mesh/D065288"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Sérogroupe - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Sérogroupe",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Sérogroupe",
"description": "Comment identifier un sérogroupe spécifique ?\nQuels tests sont utilisés pour le diagnostic ?\nPeut-on diagnostiquer par culture ?\nLes tests PCR sont-ils utiles ?\nQuel rôle joue l'historique médical ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=ErbB+Receptors&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Sérogroupe",
"description": "Quels symptômes sont associés aux infections par sérogroupe ?\nLes symptômes varient selon le sérogroupe ?\nY a-t-il des symptômes communs ?\nLes symptômes peuvent-ils être graves ?\nComment les symptômes évoluent-ils ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=ErbB+Receptors&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Sérogroupe",
"description": "Comment prévenir les infections par sérogroupe ?\nLes vaccins sont-ils efficaces ?\nQuelles mesures d'hygiène sont recommandées ?\nLes voyages augmentent-ils le risque ?\nLes comportements à risque à éviter ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=ErbB+Receptors&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Sérogroupe",
"description": "Quels traitements sont disponibles pour les infections ?\nLes traitements varient-ils selon le sérogroupe ?\nLes vaccins sont-ils disponibles ?\nComment évaluer l'efficacité du traitement ?\nY a-t-il des traitements alternatifs ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=ErbB+Receptors&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Sérogroupe",
"description": "Quelles complications peuvent survenir ?\nLes complications varient-elles selon le sérogroupe ?\nComment prévenir les complications ?\nLes complications peuvent-elles être mortelles ?\nQuels signes indiquent des complications ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=ErbB+Receptors&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Sérogroupe",
"description": "Quels sont les facteurs de risque d'infection ?\nLes antécédents médicaux influencent-ils le risque ?\nLe mode de vie joue-t-il un rôle ?\nLes voyages à l'étranger augmentent-ils le risque ?\nLes conditions environnementales influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=ErbB+Receptors&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un sérogroupe spécifique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des tests sérologiques qui détectent des anticorps spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests ELISA et l'immunofluorescence sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer par culture ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la culture de microorganismes peut aider à identifier le sérogroupe."
}
},
{
"@type": "Question",
"name": "Les tests PCR sont-ils utiles ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la PCR peut détecter des séquences spécifiques de l'ADN des microorganismes."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique aide à orienter les tests et à identifier les sérogroupes possibles."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés aux infections par sérogroupe ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient, mais incluent fièvre, douleurs et inflammation."
}
},
{
"@type": "Question",
"name": "Les symptômes varient selon le sérogroupe ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque sérogroupe peut provoquer des symptômes spécifiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes communs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue et la fièvre sont souvent communs."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être graves ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains sérogroupes peuvent entraîner des complications graves."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent s'aggraver rapidement sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections par sérogroupe ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par la vaccination, l'hygiène et l'évitement des contacts à risque."
}
},
{
"@type": "Question",
"name": "Les vaccins sont-ils efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccins peuvent réduire significativement le risque d'infection."
}
},
{
"@type": "Question",
"name": "Quelles mesures d'hygiène sont recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Se laver les mains régulièrement et éviter les contacts avec des malades."
}
},
{
"@type": "Question",
"name": "Les voyages augmentent-ils le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones à risque peut augmenter l'exposition aux sérogroupes."
}
},
{
"@type": "Question",
"name": "Les comportements à risque à éviter ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les foules et les contacts étroits avec des personnes malades."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les infections ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antibiotiques ou antiviraux sont souvent utilisés selon le sérogroupe."
}
},
{
"@type": "Question",
"name": "Les traitements varient-ils selon le sérogroupe ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque sérogroupe peut nécessiter un traitement spécifique."
}
},
{
"@type": "Question",
"name": "Les vaccins sont-ils disponibles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains sérogroupes ont des vaccins pour prévenir les infections."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par le suivi des symptômes et des tests sérologiques après traitement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements alternatifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements complémentaires peuvent être envisagés, mais doivent être validés."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme la septicémie ou des infections localisées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le sérogroupe ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque sérogroupe peut entraîner des complications spécifiques."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement précoce et approprié peut réduire le risque de complications."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être mortelles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent être graves et potentiellement mortelles."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme une aggravation des symptômes ou une nouvelle fièvre doivent alerter."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'infection ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'immunodépression et les conditions de vie."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents d'infections augmentent le risque de réinfection."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les voyages à l'étranger augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones endémiques expose à des sérogroupes spécifiques."
}
},
{
"@type": "Question",
"name": "Les conditions environnementales influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conditions comme la pollution ou le surpeuplement peuvent augmenter le risque."
}
}
]
}
]
}
Hepatocellular carcinoma (HCC) patients at advanced stages receive immunotherapy or treatment with tyrosine kinase inhibitors (TKIs) such as Sorafenib (Sora) or Lenvatinib in frontline as well as Rego...
In this study, we addressed the impact of the receptor tyrosine kinase Axl binding to its ligand Gas6 in acquiring refractoriness to TKIs. The initial responses of Axl-positive and Axl-negative cell l...
We show that HCC cells exhibiting a mesenchymal-like phenotype were less sensitive to drug treatment, linking TKI resistance to changes in epithelial plasticity. Gas6/Axl expression and activation wer...
Together, these data suggest that the inhibition of ErbBs is synthetic lethal with Rego in Axl-expressing HCC cells, showing a novel vulnerability of HCC....
Glioblastoma multiforme (GBM) is an aggressive and lethal brain cancer, which is incurable with standard cancer treatments. miRNAs have great potential to be used for gene therapy due to their ability...
Here, miR-429 was overexpressed using lentiviral vectors in U-251 and U-87 GBM cells and it was observed that the expression level of several oncogenes of the ERBB pathway, EGFR, PIK3CA, PIK3CB, KRAS,...
Altogether, miR-429 seems to be an efficient suppressor of the ERBB genetic signaling pathway and a potential therapeutic for GBM....
The ERBBprofiler assay measures compound effects on ERBB family receptors and key downstream signaling pathways that are implicated in cancer or other complex diseases. Here, we present a protocol for...
Hepatocellular carcinoma (HCC) is a highly heterogeneous and aggressive tumor. In recent years, the incidence of HCC has been increasing worldwide. Despite notable advancements in treatment methodolog...
We performed a comprehensive, narrative review of the latest literature to define the current progress of ErbB family receptors in HCC in both the pre-clinical and clinical arenas....
The ErbB family belongs to the tyrosine kinase (TK) receptor family that comprises four members. These members are closely associated with proliferation, cell cycle regulation, and migration during HC...
Through in-depth research and the application of ErbB-targeted therapy, broader avenues will be opened for the treatment of HCC and other tumors, leading to more personalized and precise treatment app...
Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorigenesis. Single agent therapy targeting EGFR or HER2 has shown clinical successes, but drug resistance often develops due to aberra...
Patients with actionable somatic mutations or amplifications in ERBB genes or actionable KRAS mutations were enrolled to receive neratinib and trametinib in this phase I dose escalation trial. The pri...
Twenty patients were enrolled with a median age of 50.5 years and a median of 3 lines of prior therapy. Grade 3 treatment-related toxicities included: diarrhea (25%), vomiting (10%), nausea (5%), fati...
Neratinib and trametinib combination was toxic and had limited clinical efficacy. This may be due to suboptimal drug dosing given drug-drug interactions....
NCT03065387....
ERBB receptor tyrosine kinases are involved in development and diseases like cancer, cardiovascular, neurodevelopmental, and mental disorders. Although existing drugs target ERBB receptors, the next g...
Gallbladder cancer (GBC) is an aggressive type of digestive system cancer with a dismal outcome. Given the lack of effective treatment options, the disease rapidly reoccurs and 5-year survival rate is...
We conduct a multicentre and randomised study on afatinib combined with gemcitabine and oxaliplatin (GEMOX) in patients with ErbB pathway mutated GBC. Clinical and biological evaluation involving ErbB...
The study was approved by the medical-ethical review committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Renji Hospital Affiliated to Shanghai Jiao Tong Uni...
NCT04183712....
Epidermal growth factor receptor (EGFR), which is referred to as ErbB1/HER1, is the prototype of the EGFR family of receptor tyrosine kinases which also comprises ErbB2 (Neu, HER2), ErbB3 (HER3), and ...
Current therapies targeting the human epidermal growth factor receptor (HER) family, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs), are limited by drug resistance and sy...
Transactivation of epidermal growth factor receptors (EGFR) provides intricate control over multiple regulatory cellular processes that merge the diversity of G protein-coupled receptors (GPCRs) with ...